Superiority of proatrial natriuretic peptide in the prognostic power in patients with acute decompensated heart failure on hospital admission: comparison with B-type natriuretic peptide and other natriuretic peptide forms

• Published in: Open heart Vol. 6; no. 2; p. e001072
• Main Authors: Takashio, Seiji, Takahama, Hiroyuki, Nishikimi, Toshio, Hayashi, Tomohiro, Nagai-Okatani, Chiaki, Matsuo, Ayaka, Nakagawa, Yasuaki, Amano, Masashi, Hamatani, Yasuhiro, Okada, Atsushi, Amaki, Makoto, Hasegawa, Takuya, Kanzaki, Hideaki, Yasuda, Satoshi, Kangawa, Kenji, Anzai, Toshihisa, Minamino, Naoto, Izumi, Chisato
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 2019; BMJ Publishing Group
• Series: Original research article
• Subjects: Biomarkers; Cardiomyopathy; Enzymes; Gene expression; Heart failure; Heart Failure and Cardiomyopathies; Patients; Plasma; Polypeptides; Studies; Japan; natriuretic peptide; acute heart failure; atrial natriuretic peptide; and b-type natriuretic peptide
• ISSN: 2053-3624; 2398-595X; 2053-3624
• DOI: 10.1136/openhrt-2019-001072

AimsThere are significant differences in how atrial (A-type) and B-type natriuretic peptide (ANP and BNP) are secreted and metabolised, but there is little information available about the relative clinical significance of the two peptides. The aim of the present study was to investigate: (1) the association between the circulating level of each ANP molecular form and patient clinical background and (2) their prognostic power for patients with acute decompensated heart failure (ADHF).MethodsWe used specific chemiluminescence enzyme immunoassays to prospectively evaluate the levels of six bioactive molecular forms of ANP (pro-ANP, β-ANP and total ANP) and BNP (pro-BNP, N-terminal pro-BNP (NT-pro-BNP) and total BNP) in plasma samples collected from 173 patients with ADHF on their hospital admission.ResultsWe found that pro-ANP levels were strongly associated with left ventricular (LV) size and ejection fraction (p<0.001), but were not associated with left atrial size. Percent pro-ANP ([pro-ANP/total ANP]x100) was also associated with LV size and function. During the follow-up term (median: 469 days), composite adverse events (all causes of death or rehospitalisation for HF) occurred in 67 patients (38.7 %). Pro-ANP was significantly associated with composite adverse events even after adjusting by estimated glomerular filtration rate (eGFR) (p<0.05). In contrast, NT-pro-BNP was not independent of eGFR in the multivariate analysis.ConclusionCirculating levels of pro-ANP are strongly associated with LV function and clinical outcomes of patients with ADHF. These findings suggest that during the acute phases of HF, pro-ANP has a prognostic power comparable with NT-pro-BNP independently of renal function.